Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients

Proteasome inhibitors (PIs) are highly active in multiple myeloma (MM) but resistance is commonly observed. All clinical stage PIs effectively inhibit chymotrypsin‐like (CT‐L) activity; one possible mechanism of resistance is compensatory hyperactivation of caspase‐like (C‐L) and trypsin‐like (T‐L)...

詳細記述

保存先:
書誌詳細
出版年:Br J Haematol
主要な著者: Levin, Nancy, Spencer, Andrew, Harrison, Simon J., Chauhan, Dharminder, Burrows, Francis J., Anderson, Kenneth C., Reich, Steven D., Richardson, Paul G., Trikha, Mohit
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley and Sons Inc. 2016
主題:
Haematological Malignancy
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5084787/
https://ncbi.nlm.nih.gov/pubmed/27161872
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14113
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料